newsfilter
← Earnings
Earnings Releases·

IDEXX Laboratories — Third Quarter 2026 Earnings Summary

IDEXX Laboratories reported third-quarter 2026 revenue of $1.214 billion, representing a 10% increase as reported and on an organic basis. Earnings per diluted share reached $4.01, an 18% rise from the prior year, driven by strong volume expansion and double-digit growth in Companion Animal Group Diagnostics recurring revenue. The company raised its full-year 2026 revenue guidance to a range of $4.741 billion to $4.767 billion and increased its EPS outlook to $14.96–$15.16. Additionally, IDEXX placed over 1,900 inVue Dx analyzers during the quarter, bringing the total installed base to nearly 11,000 instruments.

Company
IDEXX LABORATORIES INC
Sector
Healthcare
Industry
Diagnostics & Research